Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Cash & Equivalents (2022 - 2025)

Historic Cash & Equivalents for Orchestra BioMed Holdings (OBIO) over the last 4 years, with Q3 2025 value amounting to $74.0 million.

  • Orchestra BioMed Holdings' Cash & Equivalents rose 3556.42% to $74.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $74.0 million, marking a year-over-year increase of 3556.42%. This contributed to the annual value of $56.8 million for FY2024, which is 3288.39% down from last year.
  • According to the latest figures from Q3 2025, Orchestra BioMed Holdings' Cash & Equivalents is $74.0 million, which was up 3556.42% from $24.3 million recorded in Q2 2025.
  • Orchestra BioMed Holdings' Cash & Equivalents' 5-year high stood at $126.6 million during Q1 2023, with a 5-year trough of $735217.0 in Q3 2022.
  • For the 4-year period, Orchestra BioMed Holdings' Cash & Equivalents averaged around $58.4 million, with its median value being $56.8 million (2024).
  • As far as peak fluctuations go, Orchestra BioMed Holdings' Cash & Equivalents soared by 1396251.49% in 2023, and later crashed by 5490.16% in 2025.
  • Quarter analysis of 4 years shows Orchestra BioMed Holdings' Cash & Equivalents stood at $82.6 million in 2022, then rose by 2.5% to $84.6 million in 2023, then plummeted by 32.88% to $56.8 million in 2024, then surged by 30.2% to $74.0 million in 2025.
  • Its Cash & Equivalents stands at $74.0 million for Q3 2025, versus $24.3 million for Q2 2025 and $40.2 million for Q1 2025.